



~~Wednesday, March 10, 2021~~ ~~Friday, February 26, 2021~~

GLOBAL PHARMAPARTNERS, INC. – AN EXCITING INVESTMENT OPPORTUNITY FOR THE USA AND GLOBAL PHARMACEUTICAL INDUSTRY... A FAST-GROWING BUSINESS THAT WILL GROW EVEN FASTER WITH YOUR INVESTMENT.

Global PharmaPartners, Inc (GPP) is a fast growing US and global pharmaceutical business looking to expand even more rapidly by taking on investment. GPP is a US Based company in existence since 2012 to partner with many research and development pharmaceutical companies around the globe to source, develop, file with the FDA, EMA, MHRA, ANVISA, WHO and many other regulatory bodies to launch pharmaceutical products into the USA and globally. GPP has reached a point now (100% privately held company by Mr. Robert L Camerer, CEO and owner) where we will need external investment to develop complex products on our own in order to grow the business according to our current 2021 to 2025 business plan.

An investment of **approximately 10 million USD\$**, as well as commitment to further invest in valuable complex generic products, will allow you to obtain a majority stake in GPP, which we forecast to grow exponentially in the next few years (see attached ppt). Also, through our extensive relationships with development partners around the globe, we already have access to the complex generic projects we seek to invest in, as well as a great GLOBAL team to support our future growth.

If you would like to proceed in this case, then let us please discuss this attached presentation with your senior management in DETAIL with myself, our President Joseph Corsetti, and the rest of the GPP team sometime in January. Just let me know your availability or inputs. Below you find additional details regarding GPP and our plans for the future with investment.

Thank you,

Rob Camerer
Chief Executive Officer
Global PharmaPartners, Inc.

GPP Summary and Strategy Going Forward:

1. CURRENT BUSINESS MODEL: Connecting ANDA development companies with US **marketing partners** - all for a royalty. A broker model.

Goal ---convert this into a model that develops future ANDA's--and owns those ANDA's--all with a 50:50 profit split. A shift to the right on the profit curve.

2. DEVELOPMENT COMPANIES: located in US, China, Portugal, Germany, Greece, France, and India.

3. CURRENT MARKETING COMPANIES: Represent the major players in the US injectable generic market (Sandoz, etc). Marketing partners own the ANDA's and pay milestones to the development companies

for a 50/50 profit split. Milestones are standard---assume payment upon signature, submission and approval milestones--all paid by the marketing partners.

4. SUMMARY: GPP is a "DEALmaker" between development companies and marketing companies. A low risk model but one that begs the question--can they leverage all their development company relationships to become the primary marketing partner for the US market?

5. REVENUE MODEL: approximates 2.5% to 5% of US marketing partner net profits. Example--If a pharmaceutical company has \$50MM of product X net profits in the US market--GPP will earn \$1.25MM. The R&D or Development partner makes all payments to GPP--not the marketing partner. Plus, GPP would earn 10% of the milestone payments (paid by marketing partner to development partner--then to GPP) and separate monthly retainers (paid by development partners).

6. PROJECTS TO DATE: Total of 42 projects to date--26 have approval dates forecast between 2021 and 2025. Almost all are assigned marketing partners already.

7. APPROVALS SO FAR: Seven (7) FDA approvals to date. (one in 2017; two in 2018; three in 2019; two in 2020 YTD.)

FUTURE ANDA APPROVALS: Forecast shows seven in 2021; nine in 2022; seven in 2023; three in 2024

8. REVENUE: Net Profits for GPP are just starting to kick in. Net Profits are typically for 10 years after approval so up to 42 current products will capture royalties for 10 years--mainly between 2019-2034; some will flourish, some will fizzle and some won't make it--we all know that story too well. The virtual company model results in low operating expenses of about \$1MM annually with an 11% increase annually. GPP is cash flow positive in 2020 and this will only increase with new product approvals. See below.

Net Income forecast--

2021- \$1,437,102

2022- \$3,968,637

2023- \$5,683,700

2024- \$8,804,834

2025- \$18,004,955

2026- \$19,407,866

9. CONVERSION TO OWNING ANDA'S AND THEIR OWN GPP LABEL

GPP could do this with their own cash in several years, but would like to take on a capital partner to accelerate this timeline. GPP could develop 4-5 ANDA products per year going forward for this model. Each product would require about \$1.5-\$2.5MM to develop. This structure would allow a 50/50 profit split with the development company.

10. POTENTIAL INTEREST FOR INVESTOR:

Option A. GOAL: A new portfolio company. Invest in GPP, own 51-80%, and grow the pipeline with 50/50 partnerships--plus, owning all the ANDA's.

Option B. GOAL--A new portfolio company. Invest in GPP, own 51-80%, and grow the pipeline with 100% investment in developments, taking 100% of profits, filing with FDA and gaining approval, launch via new portfolio company's own pharmaceutical LABEL.

Option C. GOAL--a combination of A and B above.